D. Von Hoff

2.0k total citations · 1 hit paper
24 papers, 1.5k citations indexed

About

D. Von Hoff is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, D. Von Hoff has authored 24 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 7 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in D. Von Hoff's work include Cancer Treatment and Pharmacology (6 papers), Lung Cancer Treatments and Mutations (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). D. Von Hoff is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), Lung Cancer Treatments and Mutations (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). D. Von Hoff collaborates with scholars based in United States, Germany and France. D. Von Hoff's co-authors include Helmut Oettle, Patrick Schöffski, Yue Ma, Juan José Pérez Ruixo, Petr Karásek, Andrzej Szawłowski, Yves Humblet, Helgi van de Velde, Stephanie Post and Howard Safran and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

D. Von Hoff

23 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer

2004 616 citations Eric Van Cutsem, Helgi van de Velde et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
D. Von Hoff United States	11	1.1k	540	406	387	221	24	1.5k
Suzanne Russo United States	22	883 0.8×	658 1.2×	315 0.8×	626 1.6×	135 0.6×	73	1.7k
Jeremy Kortmansky United States	13	1.0k 0.9×	434 0.8×	269 0.7×	301 0.8×	307 1.4×	49	1.4k
Jan Cosaert United States	17	1.1k 1.0×	438 0.8×	336 0.8×	644 1.7×	125 0.6×	43	1.5k
Ramona F. Swaby United States	22	1.1k 1.0×	621 1.1×	278 0.7×	289 0.7×	316 1.4×	83	1.8k
Gregory Friberg United States	18	722 0.7×	504 0.9×	269 0.7×	318 0.8×	73 0.3×	35	1.2k
Bradley G. Somer United States	16	808 0.7×	412 0.8×	279 0.7×	304 0.8×	149 0.7×	45	1.3k
Glenwood D. Goss Canada	20	541 0.5×	526 1.0×	396 1.0×	327 0.8×	253 1.1×	39	1.2k
Fabrice Branle Switzerland	15	951 0.9×	578 1.1×	209 0.5×	796 2.1×	219 1.0×	36	1.5k
Jean–Louis Fischel France	24	1.2k 1.1×	817 1.5×	348 0.9×	599 1.5×	61 0.3×	62	1.9k
Zhimin Shao China	22	1.1k 1.1×	516 1.0×	557 1.4×	557 1.4×	86 0.4×	90	1.8k

Countries citing papers authored by D. Von Hoff

Since Specialization

Citations

This map shows the geographic impact of D. Von Hoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Von Hoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Von Hoff more than expected).

Fields of papers citing papers by D. Von Hoff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Von Hoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Von Hoff. The network helps show where D. Von Hoff may publish in the future.

Co-authorship network of co-authors of D. Von Hoff

This figure shows the co-authorship network connecting the top 25 collaborators of D. Von Hoff. A scholar is included among the top collaborators of D. Von Hoff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Von Hoff. D. Von Hoff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tibes, Raoul, Kevin T. McDonagh, Lazaros J. Lekakis, et al.. (2014). Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias. Investigational New Drugs. 33(2). 389–396. 38 indexed citations

Mahadevan, Daruka, Ruth Plummer, Matthew Squires, et al.. (2011). A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors. Annals of Oncology. 22(9). 2137–2143. 73 indexed citations

Dychter, Samuel S., Ramesh K. Ramanathan, Jon Infante, et al.. (2011). PP 60 Targeting hyaluronan in tumor stroma. Interim translational and biomarker evaluations of pegylated hyaluronidase (PEGPH20) in animal models and patients with advanced solid tumors. European Journal of Cancer. 47. S30–S31. 2 indexed citations

Desai, Neil, Daniel J. Knauer, José Iglesias, et al.. (2009). 1004 SPARC may be a predictive biomarker of response to nab-paclitaxel. European Journal of Cancer Supplements. 7(2). 88–88. 4 indexed citations

Hoch, Ute, et al.. (2009). 8015 NKTR-102 demonstrates nonclinical and phase 1 clinical anti-tumor activity in ovarian cancer. European Journal of Cancer Supplements. 7(2). 454–454. 3 indexed citations

Richards, Donald, Rajesh Ramanathan, Carlos Becerra, et al.. (2009). Dose-finding study of NKTR-102 in combination with cetuximab. Journal of Clinical Oncology. 27(15_suppl). e13503–e13503.

Oettle, Helmut, Donald Richards, Rajesh Ramanathan, et al.. (2006). A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005; 16: 1639–1645. Annals of Oncology. 17(3). 535–535. 2 indexed citations

Oettle, Helmut, Donald Richards, Rajesh Ramanathan, et al.. (2005). A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Annals of Oncology. 16(10). 1639–1645. 245 indexed citations

Cutsem, Eric Van, Helgi van de Velde, Petr Karásek, et al.. (2004). Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer. Journal of Clinical Oncology. 22(8). 1430–1438. 616 indexed citations breakdown →

10.

Taylor, Charles W., Paul C. Walker, D. Tang–Liu, et al.. (2004). A phase I and pharmacokinetic clinical trial of the orally administered retinoic acid receptor-α Agonist, AGN 195183. Journal of Clinical Oncology. 22(14_suppl). 2022–2022. 2 indexed citations

11.

Villalona‐Calero, Miguel A., Joanne L. Blum, Stephen E. Jones, et al.. (2001). A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients. Annals of Oncology. 12(5). 605–614. 39 indexed citations

12.

Levine, A, Anil Tulpule, Lawrence D. Kaplan, et al.. (1997). Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: results from a multicenter phase II trial.. Journal of Clinical Oncology. 15(3). 1094–1103. 34 indexed citations

13.

Rowinsky, Eric K., Leia M. Smith, Gladys Rodriguez, et al.. (1997). Docetaxel in combination with fluorouracil: study design and preliminary results.. PubMed. 11(6 Suppl 6). 33–5. 1 indexed citations

14.

Hoff, D. Von. (1996). Future Directions for Clinical Research With CPT-11 (Irinotecan). European Journal of Cancer. 32. S9–S12. 12 indexed citations

15.

Eckardt, John R., S. Gail Eckhardt, Miguel A. Villalona‐Calero, Ronald Drengler, & D. Von Hoff. (1995). New anticancer agents in clinical development.. PubMed. 9(11). 1191–8; 1331; discussion 1332. 9 indexed citations

16.

Berg, C. van den, Xin‐Yuan Guan, D. Von Hoff, et al.. (1995). DNA sequence amplification in human prostate cancer identified by chromosome microdissection: potential prognostic implications.. PubMed. 1(1). 11–8. 85 indexed citations

17.

Brown, T.D., Kathleen A. Havlin, Geoffrey R. Weiss, et al.. (1991). A phase I trial of taxol given by a 6-hour intravenous infusion.. Journal of Clinical Oncology. 9(7). 1261–1267. 150 indexed citations

18.

Keaton, Mark, T.D. Brown, Jesse C. Craig, et al.. (1990). Phase II study of carbetimer in non-small cell lung cancer. Investigational New Drugs. 8(4). 385–386. 2 indexed citations

19.

Strandjord, Sarah E., Ulla M. Saarinen, PI Warkentin, et al.. (1988). In vitro treatment of autologous bone marrow for neuroblastoma patients with anti GD2 monoclonal antibody and human complement: a pilot study.. PubMed. 271. 237–48. 6 indexed citations

20.

Wernz, J, Daniel L. Kisner, James M. Koeller, et al.. (1985). Doxorubicin and interferon: rationale and clinical experience.. PubMed. 12 Suppl B. 61–7. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact